American Association of Clinical Endocrinologists Release: Endocrinologists Welcome FDA Avandia Recommendation

JACKSONVILLE, FL--(MARKET WIRE)--Jul 31, 2007 -- The American Association of Clinical Endocrinologists (AACE), along with the rest of the medical community, has watched with concern the debate regarding usage of GlaxoSmithKline's rosiglitazone (Avandia) in diabetes and the question of whether it increases cardiovascular risk. AACE welcomes the recommendation of the Food and Drug Administration endocrine advisory panel, which voted almost unanimously yesterday that Avandia remain in the US market.